1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Boserolimab: new trials by email Literature Review of Boserolimab trials Research Report on Boserolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) Pembrolizumab, Carboplatin, Paclitaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 450 | 2019-12-19 | 2026-10-29 |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) Boserolimab, Pembrolizumab, Pemetrexed - Pharmacokinetics, Solid Tumor | Phase 1 | Completed | Merck Sharp & Dohme LLC | 182 | 2018-02-18 | 2025-11-05 |
Carcinoma, Non-Small-Cell Lung (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Triple Negative Breast Neoplasms (1)
Israel (2) · South Korea (2) · Spain (2) · Taiwan (2) · United States (2) · Canada (1) · Chile (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Ukraine (1)
2017 (1), 2023 (1)